Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Feb 08, 2021 4:42pm
149 Views
Post# 32504553

RE:RE:RE:RE:RE:Delay

RE:RE:RE:RE:RE:Delayaaacchhhh..,,,,,,the market is definitely anticipating dilution,,and it is probably correct to assume so,,,,,that Calgary excitiement stays true to form,,,,,,,I have no idea how a CEO can over promise and under deliver year after year missing timelines,,milestones and cost estimates, failing trial after trial and still retain the chair!!,,its an absolute head scratcher,,,,and a disgrace for the BoD,!
,,,,,The only point that we may be missing here is that the major insiders intend on delivering shares and warrants to certain entities at a fraction of this company's theoretical value,,,,,pitiful,,,no other word to desribe it,,,,,our CEO is most likely just a mouth piece for these majors,!
By the way,,,,how are our newbies and their bullish sentiment holding up??......only a few more years till you will be making such posts ,,,, lmfao!!!!,,its the bitter taste of the koolaid when failure to lanch is evident,,,,,and worse after the sweet taste of that same koolaid when first deliverd to the ears of new recuits. !!!!
<< Previous
Bullboard Posts
Next >>